- Discovery and mechanism of action of novel KV10.1 and KV1.3 potassium channel lead molecules with anti-cancer activity(2022)
Auteurs: Louise Hendrickx, Jan Tytgat, Steve Peigneur
- Design of New Potent and Selective Thiophene-Based KV1.3 Inhibitors and Their Potential for Anticancer Activity(2022)
Auteurs: Louise Hendrickx, Steve Peigneur, Jan Tytgat
- Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment(2022)
Auteurs: Louise Hendrickx, Steve Peigneur, Jan Tytgat
Pagina's: 183 - 226
- Quinazolinone dimers as a potential new class of safer Kv1 inhibitors: Overcoming hERG, sodium and calcium channel affinities(2021)
Auteurs: Steve Peigneur, Anne-Sophie Depuydt, Louise Hendrickx, Jan Tytgat
- Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges(2021)
Auteurs: Louise Hendrickx, Steve Peigneur, Jan Tytgat
Pagina's: 2423 - 2473
- 3D Pharmacophore-Based Discovery of Novel KV10.1 Inhibitors with Antiproliferative Activity(2021)
Auteurs: Louise Hendrickx, Steve Peigneur, Jan Tytgat
- Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products(2020)
Auteurs: Dongchen An, Steve Peigneur, Louise Hendrickx, Jan Tytgat
- Design and characterization of a novel structural class of Kv1.3 inhibitors(2020)
Auteurs: Louise Hendrickx, Steve Peigneur, Jan Tytgat
- Down to Counsel: Towards A Transdisciplinary Toolbox for Non-directive Counseling in Prenatal Screening for Down Syndrome(2018)
Auteurs: Louise Hendrickx, Eline Zenner
Pagina's: 38 - 76